Esperion Therapeutics ESPR Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's other income, net (note 6)?
- Esperion Therapeutics (ESPR) reported other income, net (note 6) of $1.18M in Q1 2026.
- How has Esperion Therapeutics's other income, net (note 6) changed year-over-year?
- Esperion Therapeutics's other income, net (note 6) increased by 10.4% year-over-year, from $1.07M to $1.18M.
- What is the long-term trend for Esperion Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Esperion Therapeutics's other income, net (note 6) has grown at a -3.2% compound annual growth rate (CAGR), from $3.98M to $3.49M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.